

# Activity Report

---

ESC COUNCIL OF CARDIO-ONCOLOGY

FISCAL YEAR 2021 (APRIL 2020 – MARCH 2021)

## Highlights from 2020-2021

- ➔ Over 1,700 members from multiple disciplines.
- ➔ Launch of a new series of **Cardio-Oncology Clinical Case Talks**.
- ➔ Another four interviews added to the series of **audio-interviews**
- ➔ **Three webinars** developed in different areas of cardio-oncology
- ➔ Involved in Europe's **Beating Cancer Plan**
- ➔ Contributed to the development of **four scientific documents**.

# Council of Cardio-Oncology Nucleus 2020-2022



**Thomas Suter**  
*Chairperson*



**Alexander Lyon**  
*Chairperson-Elect*



**Riccardo Asteggiano**  
*Past-Chairperson*



**Peter van der Meer**  
*Treasurer*



**Teresa Lopez Fernandez**  
*Secretary*



**Rudolf De Boer**  
*Liaison Officer*



**Ciro Santoro**  
*Communications  
Coordinator*



**Jeroen Bax**  
*Nucleus Member*



**Christopher Plummer**  
*Nucleus Member*




**Geeta Gulati**  
*Nucleus Member*

# Membership

By March 2021, the Council had attracted over 1,700 members from multiple disciplines.

The Council reaches out to members via its e-newsletter, and it also promotes discussions between different healthcare professionals on its [Facebook group](#): in March 2021, this group had over 4000 members.



# Congresses

The Council was involved in helping to build the [cardio-oncology sessions](#) during *ESC Congress 2020 – a digital experience*. Several of the Council Nucleus members had faculty roles, for example:

- Cardiotoxicity of cancer therapy: pretreatment assessment.  
Speaker: T Suter
- Prevention and treatment of heart failure in patients with cancer.  
Speaker: T Lopez Fernandez
- Drugs to prevent cardiotoxicity of cancer therapy.  
Speaker: P Van Der Meer

# Education

## Audio Interviews

During 2020-2021, the Council added another four recordings to its [audio interviews series](#). This series intends to provide real-life tips and tricks in the field of cardio-oncology.

Date	Title
04/01/2021	Long-term survivorship programmes - reality or fiction?
14/12/2020	How can cardiologists and hematologists collaborate to improve cardio-oncology structures?
09/11/2020	Cancer and Vascular Toxicity
19/10/2020	Atrial fibrillation and cancer

## Clinical Case Talks

The Council has developed a new series of [clinical case talks](#). The first talk was published in February 2021 on the topic of how to handle 5-FU cardiotoxicity.

**Case of a 66-year-old male with rectal cancer**

**Previous medical history**

- Hypertension – uses lisinopril 2,5 mg
- COPD – uses tiotropiumbromid, budesonid, formoterol, montelukast

**Oncological history**

- Distal rectal cancer, possible lung metastasis
- Neoadjuvant treatment with 4 FLOX
- Radiation and capecitabine was started as preoperative treatment. He has received 14/50 treatments.
- DPYD-analyses was normal

COPD: chronic obstructive pulmonary disease  
FLOX: 5-fluorouracil, oxaliplatin and capecitabine  
DPYD: dihydropyrimidine dehydrogenase

More talks are being developed for 2021-2022.

## Scientific Documents

The Council has been involved in the development of the following scientific documents during 2020-2021:

- [Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association \(HFA\), the European Association of Cardiovascular Imaging \(EACVI\) and the Cardio-Oncology Council of the European Society of Cardiology \(ESC\)](#)  
Published July 2020, European Journal of Heart Failure
- [The cancer patient and cardiology](#)  
Published August 2020, European Journal of Heart Failure
- [Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management](#)  
Published September 2020, European Journal of Preventive Cardiology
- [Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology](#)  
Published October 2020, European Journal of Heart Failure

## Webinars

The Council organised three webinars in 2020-2021:

Date	Title	Presenters	Host	Attendees
April 2020	<a href="#">How cardiovascular magnetic resonance may help cancer patients</a>	Valentina Püntmann, Daniel Lenihan	Jeroen Bax	657
February 2021	<a href="#">Integrating and organising cardiac imaging and biomarkers in cardio-oncology: which, when and how frequently</a>	Radek Pudil, Jelena Celutkiene	Rudolf De Boer	751
March 2021	<a href="#">The essential skill in cardio-oncology: baseline cardiotoxicity risk stratification</a>	Daniela Cardinale, Susan Dent	Alexander Lyon	851

### The essential skill in cardio-oncology: baseline cardiotoxicity risk stratification



#### Take Home Messages

1. Cardiotoxicity risk is NOT equal for cancer patients
2. Baseline CV risk stratification can identify higher risk patients
3. Communication between oncology and cardiology/cardio-oncology can improve outcomes
  - Reduce cardiovascular disease
  - Improve cancer outcomes



Alexander Lyon  
UK

## Research

At the end of 2019, the Council conducted a survey on 'Atrial fibrillation management in cardio-oncology' involving 1,146 respondents worldwide.

The results of this survey were published in September 2020 in this scientific document:

[Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management](#)

## Advocacy

The Council, in collaboration with the ESC Advocacy Committee, contributed to the EU's Cancer Beating Plan through the following initiatives:

- **Collaboration with the European Cancer Patients Coalition.**
  - Development of a White paper entitled: *The impact of cancer-related comorbidities on patient treatment, treatment efficacy, survivorship, and quality of life* -> pending publication.
  - [Joint statement](#) prepared calling for greater focus on cancer comorbidities.
  - Further joint initiatives are planned during the European Week Against Cancer
- **Collaboration with the European Cancer Organisation (ECO)**
  - [Joint letter](#) sent to J Ryan, *European Commission Health & Consumers Directorate-General*, underlining cardio-oncology issues and current needs.

The Council is working to build collaborative initiatives with other related external societies and several Council Nucleus members are currently contributing to the development of guidelines:

- from the European Hematology Association on "Cardiovascular toxicity in older adults with hematologic malignancies"
- from the European Respiratory Society (ERS) and the European Society of Thoracic Surgery (ESTS) on 'ERS/ESTS Clinical Practice Guideline on Fitness for Tumour-specific Treatments of Lung Cancer'